top of page

In The News

Press Coverage on Vesica Health

Apr 5, 2024

Vesica Health Builds Data for Follow-On Applications of Bladder Cancer Test

With plans in place to launch a urine-based molecular test for bladder cancer detection next month, Vesica Health is also gearing up to validate a second application in post-treatment patient surveillance.

In that vein, European researchers recently published a study in the journal European Urology Open Science concluding that while further validation in larger cohorts is warranted, the company's AssureDx test has the potential to reduce the use of cystoscopies in patients who have had radiation treatment for muscle-invasive bladder cancer.

Vesica Health Builds Data for Follow-On Applications of Bladder Cancer Test

Mar 27, 2024

Urine-based assay demonstrates predictive efficacy in MIBC

The AssureMDx test demonstrated an area under the curve of 0.80 in detecting urinary tract recurrences in MIBC.

Urine-based assay demonstrates predictive efficacy in MIBC

Oct 20, 2023

Startup Vesica Health to Revive MDxHealth Bladder Cancer Assay Boosted by New Clinical Impact Data

According to Vesica, the AssureDx test conferred a statistically significant improvement in the identification of patients at increased risk for bladder cancer over AUA measures alone. Notably, in patients with microhematuria, the assay showed an area under the receiver operating curve of 0.97, with a positive test result resulting in a fivefold increase in the risk of harboring bladder cancer compared to the current risk assessment metrics alone.

Startup Vesica Health to Revive MDxHealth Bladder Cancer Assay Boosted by New Clinical Impact Data

Oct 11, 2023

Urine-Based Genomic Test Identifies Hematuria Patients at High Risk for Bladder Cancer

Vesica Health’s (Irvine, CA, USA) AssureDx is a noninvasive urine test that assesses genomic changes related to bladder cancer, assisting in the identification of patients who would benefit from a clinical assessment by an urologist.

Urine-Based Genomic Test Identifies Hematuria Patients at High Risk for Bladder Cancer

Oct 10, 2023

Urine-based genomic test enhances current risk assessments for bladder cancer

In patients with microhematuria, a positive result on the test was associated with a 5-fold increase in the risk of patients harboring bladder cancer compared with current metrics alone.

Urine-based genomic test enhances current risk assessments for bladder cancer
bottom of page